Undiscovered European Gems with Promising Potential for March 2025

In This Article:

Amidst the backdrop of global trade uncertainties and economic adjustments, European markets have shown resilience, with mixed performances across major indices like Germany's DAX and France's CAC 40. As the European Central Bank navigates inflationary pressures and potential trade impacts, investors may find opportunities in small-cap stocks that are well-positioned to capitalize on regional economic shifts and strategic spending initiatives.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Ovostar Union

0.01%

10.19%

49.85%

★★★★★★

Mirbud

16.01%

27.19%

26.48%

★★★★★★

Bahnhof

NA

8.39%

14.20%

★★★★★★

La Forestière Equatoriale

NA

-58.49%

45.78%

★★★★★★

Moury Construct

2.93%

10.28%

30.93%

★★★★★☆

HOMAG Group

NA

-31.14%

23.43%

★★★★★☆

Flügger group

20.98%

3.24%

-29.82%

★★★★★☆

Sparta

NA

-5.54%

-15.40%

★★★★★☆

ABG Sundal Collier Holding

0.61%

-1.57%

-8.96%

★★★★☆☆

Practic

NA

3.63%

6.85%

★★★★☆☆

Click here to see the full list of 368 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

Faes Farma

Simply Wall St Value Rating: ★★★★★☆

Overview: Faes Farma, S.A. is involved in the research, development, production, and marketing of pharmaceutical and healthcare products as well as raw materials on a global scale, with a market cap of approximately €1.08 billion.

Operations: Faes Farma generates revenue primarily from its Pharmaceutical Products segment, contributing €457.80 million, and the Nutrition and Animal Health segment, which adds €52.30 million.

Faes Farma, a nimble player in the pharmaceuticals sector, has seen its earnings grow by 21.2% over the past year, outpacing the industry's 20.9%. With net income rising to €111.36 million from €91.9 million last year and revenue climbing to €510.04 million from €473.09 million, it’s clear they’re on an upward trajectory despite a debt-to-equity ratio increase from 3.2% to 6.9% over five years. Trading at nearly 13% below estimated fair value and with more cash than total debt, Faes Farma seems well-positioned for future challenges despite forecasts of a potential earnings decline averaging 6.3% annually over the next three years.

BME:FAE Earnings and Revenue Growth as at Mar 2025
BME:FAE Earnings and Revenue Growth as at Mar 2025

Savencia

Simply Wall St Value Rating: ★★★★★★

Overview: Savencia SA is a company engaged in the production, distribution, and marketing of dairy and cheese products across France, the rest of Europe, and internationally with a market capitalization of approximately €748.93 million.